Study Evaluating the Tolerance and Biological Activity of Oral Clioquinol in Patients With Relapsed or Refractory Hematological Malignancy

NCT00963495 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

11

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia
Acute Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
Myelodysplasia
Lymphoma, Non-Hodgkin
Hodgkin's Lymphoma
Multiple Myeloma

Interventions

DRUG: Clioquinol

Sponsor

University Health Network, Toronto